PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in chronic lymphocytic leukaemia

PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in chronic lymphocytic leukaemia

In chronic lymphocytic leukemia (CLL), mutation and loss of p53 and ATM abrogate DNA damage signalling and predict poorer response and shorter survival. We hypothesised that poly (ADP-ribose) polymerase (PARP) activity, which is crucial for repair of DNA breaks induced by oxidative stress or chemoth...

Full description

Bibliographic Details
Main Authors: Herriott, Ashleigh, Tudhope, Susan J., Junge, Gesa, Rodrigues, Natalie, Patterson, Miranda J., Woodhouse, Laura, Lunec, John, Hunter, Jill E., Mulligan, Evan A., Cole, Michael, Allinson, Lisa M., Wallis, Jonathan P., Marshall, Scott, Wang, Evelyn, Curtin, Nicola J., Willmore, Elaine
Format: Online
Language:English
Published: Impact Journals LLC 2015
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4791280/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4791280/

Similar Items